|Table of Contents|

Expression of LncRNA ZEB2-AS1 in ovarian cancer and its relationships with clinicopathological features and prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 01
Page:
111-115
Research Field:
Publishing date:

Info

Title:
Expression of LncRNA ZEB2-AS1 in ovarian cancer and its relationships with clinicopathological features and prognosis
Author(s):
LIU Yugui1; LIU Hao1; SHANG Hejiang2; LIU Lixia1; JI Mei3
1.Department of Obstetrics and Gynecology；2.Clinical Laboratory， Hebi People's Hospital, Henan Hebi 458030，China；3.Zhengzhou University，Henan Zhengzhou 450006，China.
Keywords:
ovarian cancer; long non-coding ribonucleic acid(LncRNA) zinc finger E-box binding homologous box protein 2-AS1; clinicopathological features; prognosis
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2021.01.025
Abstract:
Objective：To investigate the expression of long non-coding ribonucleic acid(LncRNA) zinc finger E-box binding homeobox protein 2-AS1(LncRNA ZEB2-AS1) in ovarian cancer，and to analyze its relationships with clinicopathological characteristics and prognosis.Methods：Ninety patients with ovarian cancer admitted to our hospital from March 2015 to March 2016 were selected as the ovarian cancer group，and fifty-two healthy volunteers were selected as the control group.Real-time fluorescence quantitative polymerase chain reaction(qRT-PCR) was used to detect the expression levels of LncRNA ZEB2-AS1.The clinicopathological data of the patients were collected.According to the results of LncRNA ZEB2-AS1 expression，patients were divided into high expression group(52 cases) and low expression group(38 cases).Its relationship with clinicopathological characteristics was analyzed.Patients with ovarian cancer were followed-up for 3 years.The relationship between the expression of LncRNA ZEB2-AS1 with the prognosis of patients was analyzed by Kaplan-Meier method.Cox proportional hazard model was used to analyze the prognostic factors of ovarian cancer patients.Results：The expression levels of serum LncRNA ZEB2-AS1 in patients with ovarian cancer were significantly higher than those in the control group(P<0.05).The expression level of LncRNA ZEB2-AS1 was significantly correlated with lymph node metastasis，FIGO staging，differentiation and CA125 level in patients with ovarian cancer(P<0.05).Kaplan-Meier analysis showed that PFS and OS were 25.00% and 46.88% respectively of patients in the LncRNA ZEB2-AS1 high expression group，while PFS and OS in the LncRNA ZEB2-AS1 high expression group were significantly lower than those in the low expression group(P<0.05).Cox multivariate analysis showed that lymph node metastasis，FIGO staging and LncRNA ZEB2-AS1 expression were independent risk factors affecting the prognosis of ovarian cancer patients(P<0.05).Conclusion：The expression of serum LncRNA ZEB2-AS1 in patients with ovarian cancer is significantly increased and is closely related to the clinicopathological characteristics and prognosis of the patients.It may serve as a marker for early diagnosis and therapeutic target of ovarian cancer.

References:

[1]NAKAMURA K，SAWADA K，MIYAMOTO M，et al.Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression［J］.Oncotarget，2019，10(6)：673-683.
[2]PiSTOLLATO F，CALDERN IGLESIAS R，RUIZ R，et al.The use of natural compounds for the targeting and chemoprevention of ovarian cancer［J］.Cancer Lett，2017，411(6)：191-200.
[3]曹康，吕海军.LncRNA ZEB2-AS1在Ⅲ期大肠癌中的表达及意义［J］.江苏医药，2017，43(23)：1690-1693. CAO K，LYU HJ.Expression and significance of lncRNA ZEB2-AS1 in colorectal cancer of stage Ⅲ［J］.Jiangsu Medical Journal，2017，43(23)：1690-1693.
[4]JAVADI S，GANESHAN DM，QAYYUM A，et al.Ovarian cancer，the revised FIGO staging system，and the role of imaging［J］.Am Journal Roentgenol，2016，206(6)：1351-1360.
[5]岳娟，刘菲，李艳红.卵巢癌早期诊断的血清肿瘤标记物研究进展［J］.国际妇产科学杂志，2015，42(5)：560-563. YUE J，LIU F，LI YH.Research progress in serum tumor markers of early diagnosis of ovarian cancer［J］.Journal Of International Obstetrics and Gynecology，2015，42(5)：560-563.
[6]余东阳，刘梓良，韩丽蓉.58例晚期卵巢癌患者发生腹腔内转移后的临床特征、疗效及预后影响因素分析［J］.实用肿瘤学杂志，2016，30(4)：321-326. YU DY，LIU ZL，HAN LR.The clinical features，curative effect and prognosis factors analysis in 58 patients with advanced ovarian cancer after intraperitoneal metastases［J］.Practical Oncology Journal，2016，30(4)：321-326.
[7]吕华兵，邢辉.长链非编码RNA在卵巢癌中的研究进展［J］.中国妇产科临床杂志，2016，17(5)：469-471. LYU HB，XING H.Research progress of long-chain non-coding RNA in ovarian cancer［J］.Chinese Journal of Clinical Obstetrics and Gynecology，2016，17(5)：469-471.
[8]WU FX，GAO HG，LIU KG，et al.The lncRNA ZEB2-AS1 is upregulated in gastric cancer and affects cell proliferation and invasion via miR-143-5p/HIF-1α axis［J］.Onco Targets and Therapy，2019，12(1)：657-667.
[9]WANG FX，ZHU W，YANG R，et al.LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/β-catenin pathway［J］.Molecular and Cellular Biochemistry，2019，11(5)：1-11.
[10]GUO Y，HU Y，HU M，et al.Long non-coding RNA ZEB2-AS1 promotes proliferation and inhibits apoptosis in human lung cancer cells［J］.Oncology Letters，2018，15(4)：5220-5226.
[11]WU X，YAN T，WANG Z，et al.LncRNA ZEB2-AS1 promotes bladder cancer cell proliferation and inhibits apoptosis by regulating miR-27b［J］.Biomedicine Pharmacotherapy，2017，96(5)：299-304.
[12]LAN T，CHANG L，WU L，et al.Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma［J］.Molecular Medicine Reports，2016，14(3)：4606-4612.
[13]Gao H，Gong N，Ma Z，et al.LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth and invasion through regulating the miR-204/HMGB1 axis［J］.Int J Biol Macromol，2018，116(5)：545-551.
[14]张青冬，汪萍萍，冯晓萍.miR-204在卵巢癌中的表达及对卵巢癌细胞增殖、侵袭的影响［J］.现代肿瘤医学，2017，25(16)：2632-2635. ZHANG QD，WANG PP，FENG XP.Expression of miR-204 in ovarian cancer and its role in ovarian cancer cells proliferation and invasion［J］.Modern Oncology，2017，25(16)：2632-2635.
[15]柯慧慧，段迎春，胡花，等.HMGB1/TLR4在卵巢癌中的表达及其与临床病理特征的关系［J］.中国妇幼保健，2018，33(10)：194-198. KE HH，DUAN YC，HU H，et al.Expression of HMGB1/TLR4 in ovarian cancer and its relationship with clinicopathological features［J］.Maternal and Child Health Care of China，2018，33(10)：194-198.
[16]刘妍，刘颖，俊梅.卵巢癌患者血清CD133和miR-145的表达与临床病理特征及预后的关系［J］.中国妇幼保健，2017，32(14)：3155-3158. LIU Y，LIU Y，JUN M.Relationships between serum CD133 and miR-145 expressions in ovarian cancer patients and clinicopathological features and prognosis［J］.Maternal and Child Health Care of China，2017，32(14)：3155-3158.
[17]温佳宇，李佳蕊.LncRNA在卵巢肿瘤研究中的新进展［J］.现代妇产科进展，2015，24(9)：706-707. WEN JY，LI JR.Recent progress of LncRNA in ovarian tumors［J］.Progress in Obstetrics and Gynecology，2015，24(9)：706-707.

Memo

Memo:
河南省科技攻关项目（编号：172102310057）
Last Update: 2020-11-30